

Emoge

1644

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/084,639
	Filing Date	February 25, 2002
	First Named Inventor	Hageman, Gregory S.
	Art Unit	1644
	Examiner Name	Not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	020618-000920US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of one-hundred and eight (8) cited references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus Reg. No. 42,271
Signature	
Date	03-24-04

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Nicole M. Wartell
Signature	
Date	3/24/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 3/24/04

TOWNSEND and TOWNSEND and CREW LLP

By: 
Nicole M. Wartell



PATENT
Attorney Docket No.: 020618-000920US
Client Reference No.: N8-80PAT3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory s. Hageman

Application No.: 10/084,639

Filed: February 25, 2002

For: DIAGNOSTICS AND
THERAPEUTICS FOR MACULAR
DEGENERATION-RELATED
DISORDERS

Examiner: Not yet assigned

Art Unit: 1644

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. This application is a Continuation-in-part of and relies upon U.S. Patent Application No. 09/845,745 (Filed 04/30/01), which is a Continuation-in-part of U.S. Patent Application No. 09/510,230 (Filed 02/22/00), for an earlier effective filing date under 35 U.S.C. §120. In accordance with 37 CFR §1.98(d), copies of those references that have been previously submitted to or cited by the Office in the parent applications are not enclosed. Copies of references A1-4, B1, C6, C27 and C51 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the



references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb
60162821 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/084,639	
			Filing Date	February 25, 2002	
			First Named Inventor	Hageman, Gregory S.	
			Art Unit	1644	
Sheet	1	of	5	Examiner Name	Not yet assigned
				Attorney Docket Number	020618-000920US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US-5,686,598	11-11-1997	North et al.	
	A2	US-5,705,380	01-06-1998	North et al.	
	A3	US 2002-0102581 A1	8-1-2002	Hageman et al.	
	A4	US 2003-0207309 A1	11-6-2003	Hageman et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	PCT	WO 97/38004	A1	10-16-1997			<input type="checkbox"/>
	B2							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60162821 v1




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/084,639
				Filing Date	February 25, 2002
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1644
				Examiner Name	Not yet assigned
Sheet	2	of	5	Attorney Docket Number	020618-000920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Bird, A. "Age-related macular disease," Br. J. Ophthalmol., 80, 2-3, 1996.		
	C2	Bird, A. "Bruch's membrane change with age," Br. J. Ophthalmol., 763, 166-168, 1992.		
	C3	Bressler, N., et al. "Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration," Retina, 14, 130-142, 1994.		
	C4	Bressler, S., et al. "Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration," Arch. of Ophthalmol., 108, 1442-1447, 1990.		
	C5	Burns, R., and Feeney-Burns, L., Transactions of the American Ophthalmologic Society, 78, 206-225, 1980.		
	C6	CHEN, H. et al. "An immunologic study of age-related macular degeneration" <i>Yan Ke Xue Bao</i> , Sept. 1993, pp. 113-120, Vol. 9, No. 3		
	C7	De La Paz, M., et al. "Analysis of the stargardt disease gene (ABCR) in age-related macular degeneration," Invest. Ophthalmol. Vis. Sci. (Suppl), 39, S915, 1980.		
	C8	Duvall, J., and Tso, M. "Cellular mechanisms of resolution of drusen after laser coagulation," Arch. Ophthalmol., 103, 694-703, 1985.		
	C9	Duvall-Young, J., et al. "Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report," Br. J. Ophthalmol., 73, 297-302, 1989.		
	C10	Eagle, R. "Mechanisms of maculopathy," Ophthalmol., 91, 613-25, 1984.		
	C11	Eisner, A., et al. "Sensitivities in older eyes with good acuity: eyes whose fellow eye has exudative AMD," Invest. Ophthalmol. Vis. Sci., 28, 1832-1837, 1987.		
	C12	Elman, M., and Fine, S. "Exudative age-related macular degeneration," in S. Ryan (Ed.), <i>The Retina</i> (pp. 175-200). St Louis: CV Mosby, 1992.		
	C13	Esser et al. "The significance of vitronectin in proliferative diabetic retinopathy," Graefes Archive for Clinical and Experimental Ophthalmology, 232 (8) 477-81, 1994.		
	C14	Farkas, T., et al. "The histochemistry of drusen," Amer. J. Ophthalmol., 71, 1206-1215, 1971.		
	C15	Farkas, T., et al. The ultrastructure of drusen," Amer. J. Ophthalmol., 71, 1196-1205, 1971.		
	C16	Feeney-Burns, et al. "Lysosomal enzyme cytochemistry of human RPE, bruch's membrane and drusen," Invest. Ophthalmol. Vis. Sci., 28, 1138-1147, 1987.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/084,639	
			Filing Date	February 25, 2002	
			First Named Inventor	Hageman, Gregory S.	
			Art Unit	1644	
			Examiner Name	Not yet assigned	
Sheet	3	of	5	Attorney Docket Number	020618-000920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C17	Feeney-Burns, L. et al. "The fate of immunoreactive opsin following phagocytosis by pigment epithelium in human and monkey retinas," Invest. Ophthalmol. Vis. Sci., 29, 708-719, 1988.		
	C18	Feeney-Burns, L., and Ellersieck, M. "Age-related changes in the ultrastructure of bruch's membrane," Amer. J. Ophthalmol., 100, 686-697, 1985.		
	C19	Frenneson, I., and Nilsson, S. "Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective, randomised trial," Eur. J. Ophthalmol., 6, 307-314, 1996.		
	C20	Frenneson, C., et al. "Colour contrast sensitivity in patients with soft drusen, an early stage of ARM, ", Documenta Ophthalmologica, 90, 377-86, 1995.		
	C21	Grossiklaus, et al. "Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration," American Journal of Ophthalmology 114 (4), 464-72, 1992.		
	C22	Hageman, et al. " Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells," FASEB Journal, 13(3), 477-84, 1999.		
	C23	Heidenkummer, et al. "Surgical extraction of subretinal pseudotumors in age related macular degeneration," Ophthalmologie, 92 (5), 631-639, 1995.		
	C24	Holz, F., et al. "Analysis of lipid deposits extracted from human macular and peripheral bruch's membrane," Arch. Ophthalmol., 112, 402-406, 1994.		
	C25	Ishibashi, T., et al. "Formation of drusen in the human eye," Amer. J. Ophthalmol., 101, 342-353, 1986.		
	C26	Ishibashi, T., et al. "Pathogenesis of drusen in the primate," Invest. Ophthalmol. Vis. Sci., 27, 184-193, 1986.		
	C27	KELTNER, JL & THIRKILL, CE "The 22-kDa antigen in optic nerve and retinal diseases" J. Neuroophthamol., June 1999, pp. 71-83, Vol. 19, No. 2.		
	C28	Killingsworth, M., et al. "Macrophages related to bruch's membrane in age-related macular degeneration," Eye, 4, 613-621, 1990.		
	C29	Klaver et al., "Genetic association of apolipoprotein E with age-related macular degeneration," Am J. of Human Genetics, 63 (1), 200-6, 1998.		
	C30	Lewis, H., et al. "Chorioretinal Junction, multiple extramacular drusen," Ophthalmol., 93, 1098-1112, 1986.		
	C31	Loeffler, K., and Mangini, M. "Immunolocalization of ubiquitin and related enzymes in human retina and retinal pigment epithelium," Graefe's Arch. Clin. Exp. Ophthalmol., 235, 248-54, 1997.		
	C32	Loeffler, K., et al. "Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina," Invest. Ophthalmol. Vis. Sci., 36, 24-31, 1995.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/084,639		
		Filing Date	February 25, 2002		
		First Named Inventor	Hageman, Gregory S.		
		Art Unit	1644		
		Examiner Name	Not yet assigned		
Sheet	4	of	5	Attorney Docket Number	020618-000920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C33	Midena, E., et al. "Macular function impairment in eyes with early age-related macular degeneration," Invest. Ophthalmol. Vis. Sci., 38, 469-477, 1997.	
	C34	Newsome, D., et al. "Detection of specific extracellular matrix molecules in drusen, bruch's membrane and ciliary body," Amer. J. Ophthalmol., 104, 373-381, 1987.	
	C35	Newsome, D., et al. "Macular degeneration and elevated serum ceruloplasmin," Invest. Ophthalmol. Vis. Sci., 27, 1675-80, 1986.	
	C36	Pauleikhoff, D., et al. "Drusen as risk factors in age-related macular disease," Amer. J. Ophthalmol., 109, 38-43, 1990.	
	C37	Pauleikhoff, D., et al. "Correlation between biochemical composition and fluorescein binding of deposits in bruch's membrane," Ophthalmol., 99, 1548-1553, 1992.	
	C38	PENFOLD, P. et al. "Modulation of major histocompatibility complex II expression in retinas with age-related macular degeneration," Invest. Ophthalmol. Vis. Sci., 38, 2125-33, 1997.	
	C39	PENFOLD, P. et al. "Senile macular degeneration," Invest. Ophthalmol. Vis. Sci., 27, 364-71, 1986.	
	C40	PENFOLD, P. et al. "Senile macular degeneration: the involvement of immunocompetent cells," Graefe's Arch. Clin. Exp. Ophthalmol., 223, 69-76, 1985.	
	C41	Sarks, J., et al. "Evolution of soft drusen in age-related macular degeneration" (1994), Eye, 8, 269-283.	
	C42	Sarks, S. "Aging and degeneration in the macular region: a clinico-pathological study," Br. J. Ophthalmol., 60, 324-341, 1976.	
	C43	Sarks, S. "Drusen and their relationship to senile macular degeneration," Aust. J. Ophthalmol., 8, 117-30, 1980.	
	C44	Sarks, S. "Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium," Austr. J. Ophthalmol., 10, 91-97, 1982.	
	C45	Sarks, S., and Sarks, J. "Age-related macular degeneratio: atrophic form," in S. Ryan (Ed.), The Retina St. Louis: CV Mosby, 1989.	
	C46	Sarks, S., et al. , Patterns in macular degeneration. In S. Ryan, A. Dawson, and H. Little (Eds.), Retinal Diseases (pp. 87-93). Orlando: Grune and Stratton, 1985.	
	C47	Sarks, S., et al. "Softening of drusen and subretinal neovascularization," Trans. Ophthalmol. Soc. U.K., 100, 414-422, 1980.	
	C48	Sokal, I. et al. "GCAP1(Y99C) mutant is constitutively active in autosomal dominant cone dystrophy," Mol. Cell. 2:129-133, 1998.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/084,639
				Filing Date	February 25, 2002
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1644
				Examiner Name	Not yet assigned
Sheet	5	of	5	Attorney Docket Number	020618-000920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C49	Souied, et al. "The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration," Am. J. of Ophthalmology, 125 (3) 353-9, 1998.		
	C50	Spraul, C., and Grossniklaus, H. "Characteristics of drusen and bruch's membrane in postmortem eyes with age-related macular degeneration," Arch. Ophthalmol., 115, 267-73, 1997.		
	C51	TSO, MO "Experiments on visual cells by nature and man: in search of treatment for photoreceptor degeneration. Friedenwald lecture." Invest Ophthalmol Vis Sci, Dec 1989, pp. 2430-2454, Vol. 30, No. 12.		
	C52	van der Schaft, T., et al. "Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study," Br. J. Ophthalmol., 77, 657-661, 1993.		
	C53	Vinding, T. "Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration," Acta Ophthalmologica, 68, 410-414, 1990.		
	C54	Young, R. "Pathophysiology of age-related macular degeneration" Surv. Ophthalmol., 31, 291-306, 1987.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.